GoodRx Holdings, Inc. released its financial results for the fourth quarter and full year 2024. For Q4 2024, revenue was $198.6 million, a 1% increase year-over-year, slightly missing the company's guidance of approximately $200 million. Prescription transactions revenue increased 0.8% to $144.9 million, while subscription revenue declined 10.7% to $20.68 million.
Full year 2024 total revenue reached $792.3 million, up 6% from 2023, falling slightly below the guidance of approximately $794 million. Prescription transactions revenue for the full year grew 5% to $577.5 million, driven by a 7% increase in Monthly Active Consumers. Pharma Manufacturer Solutions revenue demonstrated strong growth, increasing 26% to $107.2 million for the full year.
Net income for FY 2024 was $16.4 million, a significant improvement from a net loss of $8.9 million in 2023. Adjusted EBITDA for the full year was $260.2 million, representing 20% growth year-over-year, with an Adjusted EBITDA Margin of 32.8%, up from 28.6% in 2023.
Looking ahead, GoodRx provided guidance for the first quarter of 2025, expecting revenue between $201 million and $205 million, and an Adjusted EBITDA Margin of approximately 33%. For the full year 2025, the company anticipates revenue between $810 million and $840 million, representing 2% to 6% growth, and Adjusted EBITDA between $270 million and $286 million, indicating 4% to 10% growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.